<p>Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model</p>

Abstract

RGTZ attenuates the progression of HN through inhibiting TGF-β signaling, suppressing epithelial-to-mesenchymal transition, reducing inflammation, and lowering serum uric acid levels by preserving expression of urate transporters.